# OrsoBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orsobio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.orsobio.com/
- Total disclosed funding: $125M
- Latest round: Series B (Aug 14, 2024)
- Investors on record: 9

## About

Founded in 2021 and based in California, US, OrsoBio, Inc. is a biopharmaceutical company that develops therapies to treat severe metabolic disorders. As of 2023, the company is headed by its CEO Mani Subramanian, who founded the firm. In August 2024, OrsoBio, Inc. raised USD 67 million in Series B funding co-led by Ascenta Capital and Woodline Partners, with participation from Eli Lilly and Company Limited, Enavate Sciences, Longitude Capital, NuevaBio, and Samsara Biocapital.

The company develops treatments for individuals suffering from severe metabolic conditions, such as type 2 diabetes, severe dyslipidemias, lipodystrophies, nonalcoholic steatohepatitis, and more. The firm therapies restore energy homeostasis that helps in the treatment of severe metabolic disorders.

The company plans to use the November 2023 funding to enhance the development of its product platform on obesity and other metabolic disorders.

## Funding rounds

- Series B, Aug 14, 2024, $40M — Longitude Capital, Eli Lilly and Company Limited, Samsara BioCapital, Enavate Sciences, Woodline Partners, Ascenta Capital, Nueva Bio
- Series A, Oct 27, 2023, $85M — Longitude Capital, Eli Lilly and Company Limited, Samsara BioCapital, Patient Square Capital, NuevaBio

## Investors

- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Eli Lilly and Company Limited — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series A
- NuevaBio — Series A
- Enavate Sciences — Series B
- Woodline Partners — Series B
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series B
- Nueva Bio (https://capitalatlas.ai/funds/nueva-bio) — Series B